MXPA02011727A - Neuroprotective peptides. - Google Patents

Neuroprotective peptides.

Info

Publication number: MXPA02011727A
Authority: MX; Mexico
Prior art keywords: neuroprotective peptides; neuroprotective; peptides
Prior art date: 2000-05-26

Application number

MXPA02011727A

Other languages

Spanish (es)

Inventor

Linda Jolliffe

Original Assignee

Johnson & Johnson

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-26

Filing date

2001-05-23

Publication date

2003-10-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22771463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA02011727(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-05-23 Application filed by Johnson & Johnson filed Critical Johnson & Johnson

2003-10-24 Publication of MXPA02011727A publication Critical patent/MXPA02011727A/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Hematology (AREA)
Psychology (AREA)
Psychiatry (AREA)
Molecular Biology (AREA)
Virology (AREA)
Immunology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Toxicology (AREA)

MXPA02011727A 2000-05-26 2001-05-23 Neuroprotective peptides. MXPA02011727A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US20765400P	2000-05-26	2000-05-26
PCT/US2001/016654 WO2001091780A1 (en)	2000-05-26	2001-05-23	Neuroprotective peptides

Publications (1)

Publication Number	Publication Date
MXPA02011727A true MXPA02011727A (en)	2003-10-24

Family

ID=22771463

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MXPA02011727A MXPA02011727A (en)	2000-05-26	2001-05-23	Neuroprotective peptides.

Country Status (11)

Country	Link
EP (1)	EP1296702A4 (en)
JP (1)	JP2003534384A (en)
CN (1)	CN1318084C (en)
AU (2)	AU2001274904B2 (en)
BR (1)	BR0111182A (en)
CA (1)	CA2410453A1 (en)
IL (1)	IL153079A0 (en)
MX (1)	MXPA02011727A (en)
NZ (1)	NZ522924A (en)
WO (1)	WO2001091780A1 (en)
ZA (1)	ZA200210304B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030166003A1 (en) *	1999-06-14	2003-09-04	Cochran Andrea G.	Structured peptide scaffold for displaying turn libraries on phage
DE60020366T2 (en)	1999-06-14	2006-02-02	Genentech Inc., San Francisco	STRUCTURED PEPTIDE EQUIPMENT FOR EXHIBITING ROTATION LIBRARIES TO PHAGE
US7078376B1 (en)	2000-08-11	2006-07-18	Baxter Healthcare S.A.	Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
US6914123B2 (en)	2001-04-17	2005-07-05	Genentech, Inc.	Hairpin peptides with a novel structural motif and methods relating thereto
TWI353991B (en)	2003-05-06	2011-12-11	Syntonix Pharmaceuticals Inc	Immunoglobulin chimeric monomer-dimer hybrids
ES2333598T5 (en)	2003-05-06	2013-09-04	Biogen Idec Hemophilia Inc	CHEMICAL PROTEINS OF FC COAGULATION FACTOR TO TREAT HEMOPHILIA.
US7348004B2 (en) *	2003-05-06	2008-03-25	Syntonix Pharmaceuticals, Inc.	Immunoglobulin chimeric monomer-dimer hybrids
CA2525497A1 (en)	2003-05-12	2004-11-25	Affymax, Inc.	Peptides that bind to the erythropoietin receptor
BRPI0411160A (en)	2003-05-12	2006-07-11	Affymax Inc	new poly (ethylene glycol) modified compounds and their uses
AU2004238364A1 (en)	2003-05-12	2004-11-25	Affymax, Inc.	Spacer moiety for poly(ethylene glycol) -modified peptides
AU2004238870B8 (en)	2003-05-12	2010-04-15	Affymax, Inc.	Novel peptides that bind to the erythropoietin receptor
US7589063B2 (en)	2004-12-14	2009-09-15	Aplagen Gmbh	Molecules which promote hematopoiesis
EP1848461A2 (en)	2005-02-16	2007-10-31	Nektar Therapeutics Al, Corporation	Conjugates of an epo moiety and a polymer
US7550433B2 (en)	2005-06-03	2009-06-23	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
EP1857463A1 (en) *	2006-05-03	2007-11-21	Ebewe Pharma Ges.m.b.H. Nfg. KG	Peptide having neuroprotective effects
EP2035041B1 (en)	2006-06-30	2020-01-08	Syntab Therapeutics GmbH	Conjugates for innate immunotherapy of cancer
CA2676820A1 (en)	2007-01-31	2008-08-07	Affymax, Inc.	Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules
EP2018835B1 (en)	2007-07-09	2014-03-05	Augustinus Bader	Agent-eluting plaster
SG10202011946PA (en) *	2008-01-22	2020-12-30	Araim Pharmaceuticals Inc	Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
CA2750519C (en)	2009-02-05	2018-09-25	Immunogen, Inc.	Benzodiazepine derivatives
RU2410392C2 (en)	2009-02-16	2011-01-27	Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН	Dipeptide mimetics of ngf and bdnf neurotrophins
EP2590666B1 (en)	2010-07-06	2017-04-26	Augustinus Bader	Topical application of erythropoietin for use in the treatment of injuries of the cornea
SG191965A1 (en) *	2011-02-15	2013-08-30	Immunogen Inc	Methods of preparation of conjugates
EP3021863A4 (en) *	2013-07-17	2017-01-04	Araim Pharmaceuticals, Inc.	Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
CN105017406B (en) *	2014-04-21	2020-10-09	上海市第一人民医院	A new class of peptides with neuroprotective function
CN105233256A (en) *	2015-10-28	2016-01-13	中国人民解放军第三军医大学	Application of erythropoietin and erythropoietin derivatives to preparation of medicine for promoting apoptotic cell clearance during disease treatment
GB201609083D0 (en)	2016-05-24	2016-07-06	Syntab Therapeutics Gmbh	Synthetic compound
KR20210060536A (en) *	2018-09-14	2021-05-26	에포-메드 가부시키가이샤	Anti-erythropoietin receptor peptide
WO2025262329A1 (en)	2024-06-21	2025-12-26	Syntab Therapeutics Gmbh	Synthetic molecules comprising tlr2 ligands

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5767078A (en) *	1995-06-07	1998-06-16	Johnson; Dana L.	Agonist peptide dimers
US6165783A (en) *	1997-10-24	2000-12-26	Neuro Spheres Holdings Ltd.	Erythropoietin-mediated neurogenesis
US6660843B1 (en) *	1998-10-23	2003-12-09	Amgen Inc.	Modified peptides as therapeutic agents

2001
- 2001-05-23 CA CA002410453A patent/CA2410453A1/en not_active Abandoned
- 2001-05-23 AU AU2001274904A patent/AU2001274904B2/en not_active Ceased
- 2001-05-23 NZ NZ52292401A patent/NZ522924A/en not_active IP Right Cessation
- 2001-05-23 IL IL15307901A patent/IL153079A0/en unknown
- 2001-05-23 BR BR0111182-5A patent/BR0111182A/en not_active Application Discontinuation
- 2001-05-23 MX MXPA02011727A patent/MXPA02011727A/en unknown
- 2001-05-23 WO PCT/US2001/016654 patent/WO2001091780A1/en not_active Ceased
- 2001-05-23 JP JP2001587795A patent/JP2003534384A/en active Pending
- 2001-05-23 EP EP01941562A patent/EP1296702A4/en not_active Withdrawn
- 2001-05-23 AU AU7490401A patent/AU7490401A/en active Pending
- 2001-05-23 CN CNB018131794A patent/CN1318084C/en not_active Expired - Fee Related
2002
- 2002-12-19 ZA ZA200210304A patent/ZA200210304B/en unknown

Also Published As

Publication number	Publication date
JP2003534384A (en)	2003-11-18
EP1296702A4 (en)	2005-05-11
AU7490401A (en)	2001-12-11
CA2410453A1 (en)	2001-12-06
WO2001091780A1 (en)	2001-12-06
ZA200210304B (en)	2004-03-19
CN1318084C (en)	2007-05-30
CN1452492A (en)	2003-10-29
BR0111182A (en)	2004-02-25
IL153079A0 (en)	2003-06-24
NZ522924A (en)	2004-12-24
AU2001274904B2 (en)	2006-08-31
EP1296702A1 (en)	2003-04-02
HK1058484A1 (en)	2004-05-21

Publication	Publication Date	Title
MXPA02011727A (en)	2003-10-24	Neuroprotective peptides.
MXPA03005445A (en)	2003-09-10	I2.
MXPA03002410A (en)	2003-06-19	4-amino-quinazolines.
ZA200205479B (en)	2003-12-31	Novel biarylcarboxamides.
GB0014870D0 (en)	2000-08-09	Peptides
MXPA03002256A (en)	2003-09-10	Modified factor viii.
ZA200101012B (en)	2002-08-06	Pharmaceutical combinations.
EG23262A (en)	2004-10-31	Delta -pyrrolines.
MXPA03001591A (en)	2003-09-10	10-aryl-11-h.
MXPA03001877A (en)	2003-06-24	2-guanidino-4-aryl-quinazoline.
MXPA03002668A (en)	2003-08-20	Sulfonylguanidine.
MXPA03001991A (en)	2003-06-24	Novel arylalkane-sulfonamides.
SI1294381T1 (en)	2006-04-30	Neuroprotective 7-beta-hydroxysteroids
MXPA03002411A (en)	2003-06-19	4-amino-quinazolines.
MXPA03005714A (en)	2003-10-06	Sulfamidothienopyrimidines.
GB0029777D0 (en)	2001-01-17	Peptides
MXPA03005494A (en)	2003-10-06	Benzoylpyridazines.
MXPA03002521A (en)	2004-02-12	Triazolo-epothilones.
GB0001825D0 (en)	2000-03-22	Peptides
GB0002612D0 (en)	2000-03-29	C.m.e
AU2001278975A1 (en)	2002-02-05	Alpha-conotoxin peptides
GB0007263D0 (en)	2000-05-17	Peptides
GB0007510D0 (en)	2000-05-17	D.o.t.t.s
EP1323731A4 (en)	2005-02-09	Novel peptides
ZA200302241B (en)	2004-03-23	Triazolo-epothilones.